Company: NCEL
Filing Date: 2025-01-28
Form Type: 425
Source: 0001213900-25-007315
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-01-28
Form: 425
Chunk 4
---

of secreting insulin to generate an innovative treatment intended for the potential cure of type 1 diabetes.

Following the Merger, NLS and Kadimastem expect to continue developing NLS's promising, first-in class Dual Orexin Agonist platform within the combined company. The remaining NLS assets are expected to be divested subject to a contingent value rights agreement, the proceeds of which will be distributed entirely to the current shareholders of NLS. For more information, please visit www.nlspharma.com.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf",
allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells
(hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the
treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company's treatment for diabetes. IsletRx is comprised
of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with
insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor
Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development
of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

<div align='center'>3</div>

Safe Harbor Statement

This press release contains expressed or implied forward-looking statements
pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the use of Mazindol as
a potential novel treatment for fentanyl dependence, regulatory approval timelines, clinical trial outcomes, market acceptance and its
expected preclinical program. Further, NLS and Kadimastem are using forward-looking statements when they discuss the expected closing
of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their respective shareholders, as well as the
expected strategic position of the combined company following the merger, if completed. These forward-looking statements and their implications
are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors and uncertainties